Lifecore Renews Manufacturing Agreement with Alcon, Inc.
31 Gennaio 2008 - 10:04PM
Business Wire
LIFECORE BIOMEDICAL, INC. (NASDAQ:LCBM) announced today that it has
renewed its manufacturing agreement with Alcon Pharmaceuticals,
Ltd., a subsidiary of Alcon, Inc. (NYSE:ACL), the world�s leading
eye care company. Lifecore supplies hyaluronan to Alcon for use in
Viscoat� ophthalmic viscoelastic solution, which doctors use in eye
surgeries such as cataract extraction and intraocular lens
implantation. The new agreement extends through December, 2013 and
retains minimum purchase commitments and other features of the
previous agreement. �Renewal of the agreement extends Lifecore�s
long-standing relationship with our largest customer and the leader
in the ophthalmic market,� said Lifecore President and CEO, Dennis
J. Allingham. �We are pleased that the renewal term has been
extended by five years, and believe it provides another strong
indication of Lifecore�s commitment and capability to secure and
hold partnerships with medical market leaders.� Lifecore Biomedical
develops, manufactures, and markets biomaterials and medical
devices for use in various surgical markets through two divisions,
the Hyaluronan Division and the Dental Division. The Hyaluronan
Division primarily conducts its business through OEM and contract
manufacturing alliances in the ophthalmic, orthopedic and
veterinary medical fields. The Dental Division conducts its dental
surgery business through direct sales and marketing in the United
States, Germany, Italy, Sweden, and France, and through
distributors in 49 other countries. Certain statements in this
release are forward-looking statements as defined in the Private
Securities Litigation Reform Act of 1995, including references
regarding the strategic value of the agreement and statements
related to the growth of the hyaluronan business. Because of
numerous risks and uncertainties in the complex regulatory and
competitive aspects of Lifecore�s business activity, including
continued sales by Alcon of its Viscoat product, actual results may
differ materially from anticipated results. Investors are strongly
cautioned to review more detailed discussions of those risks
presented in the Company�s Annual Report on Form 10-K for the
fiscal year ending June 30, 2007, and other more recent filings.
General corporate information is available on the internet at
www.lifecore.com.
Grafico Azioni Lifecore Biomedical (MM) (NASDAQ:LCBM)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Lifecore Biomedical (MM) (NASDAQ:LCBM)
Storico
Da Giu 2023 a Giu 2024
Notizie in Tempo Reale relative a Lifecore Biomedical (MM) (NASDAQ): 0 articoli recenti
Più Lifecore Biomedical, Inc. Articoli Notizie